Finance

Beta
Lists
001540:KOSDAQ
AHN-GOOK PHARMACEUTICAL Co Ltd
₩10,870.00
+1.59%
(+170.00) 1D
Jun 10, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 001540...
Open
₩10,750
High
₩11,110
Low
₩10,580
Mkt. cap
141.77B
Avg. vol.
496.67K
Volume
186.19K
Dividend
5.82%
Quarterly dividend
₩158
Ex-dividend date
Dec 27, 2023
P/E ratio
7.59
52-wk high
₩12,730
52-wk low
₩7,280
EPS
₩1,431
Shares outstanding
13.04M
No. of employees
391
Open
₩10,750
High
₩11,110
Low
₩10,580
Mkt. cap
141.77B
Avg. vol.
496.67K
Volume
186.19K
Dividend
5.82%
Quarterly dividend
₩158
Ex-dividend date
Dec 27, 2023
P/E ratio
7.59
52-wk high
₩12,730
52-wk low
₩7,280
EPS
₩1,431
Shares outstanding
13.04M
No. of employees
391
News stories
From sources across the web
About AHN-GOOK PHARMACEUTICAL Co Ltd
CEOWon Deok-kwon
Employees391
Founded1959
Headquarters-
SectorPharmaceutical industry
Websiteahn-gook.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
76.82B
77.69B
76.61B
98.93B
Cost of goods sold
27.26B
26.19B
25.67B
32.81B
Cost of revenue
27.26B
26.19B
25.67B
32.81B
Research and development expenses
5.21B
4.68B
12.66B
3.81B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
38.97B
41.21B
43.59B
45.53B
Operating expense
44.60B
46.62B
56.84B
50.10B
Total operating expenses
71.86B
72.81B
82.52B
82.91B
Operating income
4.97B
4.88B
-5.91B
16.02B
Other non operating income
-282.45M
5.71M
455.18M
-291.62M
EBT including unusual items
4.19B
4.43B
-5.52B
15.84B
EBT excluding unusual items
4.13B
4.30B
-6.27B
15.35B
Income tax expense
1.12B
1.07B
-2.91B
3.45B
Effective tax rate
26.71%
24.15%
52.69%
21.77%
Other operating expenses
-
-
-
-
Net income
3.11B
3.37B
-2.58B
12.37B
Net profit margin
4.05%
4.33%
-3.37%
12.51%
Earnings per share
-
-
-
-
Interest and investment income
97.19M
105.12M
122.27M
93.74M
Interest expense
-698.53M
-661.98M
-647.18M
-634.58M
Net interest expenses
-601.33M
-556.87M
-524.92M
-540.83M
Depreciation and amortization charges
680.40M
676.60M
458.82M
647.54M
EBITDA
7.14B
7.06B
-3.66B
18.38B
Gain or loss from assets sale
1.00K
1.00K
-25.97M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer